지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.12
- 수록면
- 253 - 261 (9page)
이용수
초록· 키워드
오류제보하기
Objectives：This study aimed to investigate the efficacy and safety of Metadate CD (MCD) when given to Korean children and adolescents with attention-deficit hyperactivity disorder (ADHD). We also explored the effects of the drug on diverse neurocognitive functions.
Methods：Ninety-one subjects with ADHD (mean age 8.6±2.2 years) were recruited at 6 outpatient clinics in Seoul, Korea. We used the ADHD Rating Scale (ARS), Clinical Global Impression (CGI), and comprehensive attention test (CAT) to measure the drug?s effects.
Results： After 0.92±0.32mg/kg/day of MCD were administered for 57.4±7.6 days, there was a 48.5% reduction in the mean total ARS scores (p＜.001). Fifty-seven subjects (64.8%) showed either much improved or very much improved outcomes on the CGI-Improvement scale. The CGI-Severity scale also decreased from an average of 4.7 to an average of 2.9 (p＜.001). Errors and response time standard deviations of the CAT, sustained attention test-to-response tasks, the flanker test, and divided attention test scores decreased after treatment (p＜.05). The forward memory span of the spatial working memory test scores increased (p＜.05). Thirty-five patients (39.8%) experienced side effects, of which the most common were headache (14.8%), nausea (12.5%), and anorexia (9.1%).
Conclusion：This open-label study suggests that MCD is effective and safe in improving the symptoms and neurocognitive functions of Korean children and adolescents with ADHD.
Methods：Ninety-one subjects with ADHD (mean age 8.6±2.2 years) were recruited at 6 outpatient clinics in Seoul, Korea. We used the ADHD Rating Scale (ARS), Clinical Global Impression (CGI), and comprehensive attention test (CAT) to measure the drug?s effects.
Results： After 0.92±0.32mg/kg/day of MCD were administered for 57.4±7.6 days, there was a 48.5% reduction in the mean total ARS scores (p＜.001). Fifty-seven subjects (64.8%) showed either much improved or very much improved outcomes on the CGI-Improvement scale. The CGI-Severity scale also decreased from an average of 4.7 to an average of 2.9 (p＜.001). Errors and response time standard deviations of the CAT, sustained attention test-to-response tasks, the flanker test, and divided attention test scores decreased after treatment (p＜.05). The forward memory span of the spatial working memory test scores increased (p＜.05). Thirty-five patients (39.8%) experienced side effects, of which the most common were headache (14.8%), nausea (12.5%), and anorexia (9.1%).
Conclusion：This open-label study suggests that MCD is effective and safe in improving the symptoms and neurocognitive functions of Korean children and adolescents with ADHD.
목차
서론
방법
결과
고찰
결론
References
참고문헌 (2)
참고문헌 신청
이 논문의 저자 정보
이 논문과 함께 이용한 논문
국내 아동 및 청소년 주의력 평가를 위한 종합주의력검사의 표준화 연구
유한익
,
이중선
,
강성희
외 7명
소아청소년정신의학
2009
.06
Anorexia Nervosa의 사회성 함양을 위한 댄스/동작치료의 효과검증을 위한 사례연구
김나영
,
장경호
한국사회체육학회지
2003
.11
내관 지압과 심상요법이 방사성요오드 치료를 받는 갑상선암 환자의 오심, 구토, 헛구역질 및 식욕부진에 미치는 효과
강미경
,
서은영
Asian Oncology Nursing
2013
.12
대학생에서 야식의 섭취가 영양소 섭취 상태에 미치는 영향
홍승희
,
연지영
,
배윤정
동아시아식생활학회지
2013
.06
Management of anorexia and weight loss in cancer patients
서광옥
대한임상종양학회 학술대회지
2009
.09
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2014-516-000733542